The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness
In the field of general anesthesia research, the neural mechanism underlying the loss of consciousness has long been a highly core issue. It remains unclear what consciousness is and how it emerges from brain activity. By studying anesthesia and sleep, the investigators aim to reveal what happens in the brain when cons
| Condition(s) | Consciousness, Level Altered |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | In the field of general anesthesia research, the neural mechanism underlying the loss of consciousness has long been a highly core issue. It remains unclear what consciousness is and how it emerges from brain activity. By studying anesthesia and sleep, the investigators aim to reveal what happens in the brain when consciousness is lost and when it returns. Dexmedetomidine, a widely used drug in clinical anesthetic practice, plays an important role in the anesthetic process due to its unique pharmacological properties. It hardly causes respiratory depression during the sedative and hypnotic process, which makes it occupy an important position in clinical anesthetic regimens. The emergence of stereoelectroencephalography (SEEG) technology has brought new opportunities for research on anesthe |
| Who can participate | Inclusion Criteria: 1. Age range: 1 - 65 years old 2. BMI: 18.5 - 25.0 kg/m² 3. ASA physical status classification: I - III 4. Patients diagnosed with drug - refractory epilepsy who, after long - term monitoring of epileptic seizures, require stereo-electroencephalography (SEEG) electrode implantation based on the clinical need for monitoring their epilepsy. 5. Patients voluntarily participate in this study and sign a written informed consent form. Exclusion Criteria: 1. Patients with severe arrhythmia or other organic heart diseases; 2. Patients with comorbid obstructive sleep apnea-hypopnea syndrome (OSAHS); 3. Patients with hepatic or renal dysfunction; those with a history of immunodeficiency diseases , or a history of cancer/malignant tumors, or a history of autoimmune diseases, or se |
| Ages | 3 Years to 65 Years |
| Sex | All |
| Lead sponsor | Guangzhou General Hospital of Guangzhou Military Command |
| Locations | Guangzhou, Guangdong, China |
| Start date | 2025-04-10 |
| NCT ID | NCT07145697 |
| Official listing | https://clinicaltrials.gov/study/NCT07145697 |